{"product_id":"retatrutide-3d-60mg-uae","title":"Retatrutide 3D 60mg UAE: 60mg\/3ml Pen \u0026 Product Guide","description":"\u003ch1\u003eRetatrutide 3D 60mg UAE: Pen Format, Clinical Development \u0026amp; Product Guide\u003cimg class=\"_resizableImage_1wqvo_111\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0745\/6315\/8104\/files\/Oaxx4LmyXgJxb99Ty8apE0KE2xLIHpcQKnLn2mig.png?v=1788094633\"\u003e\n\u003c\/h1\u003e\u003cp\u003eRetatrutide 3D 60mg UAE is a product listing associated with retatrutide, an investigational compound being studied in clinical development. The supplied packaging identifies the product as RETATRUTIDE 3D, with 60mg\/3ml shown on the box and states that one pen contains 5 doses.\u003c\/p\u003e\u003cp\u003eRetatrutide is also known by the development code LY3437943 and is being investigated as a triple hormone receptor agonist involving GIP, GLP-1 and glucagon pathways. Current clinical development includes multiple Phase 3 and Phase 3b studies.\u003c\/p\u003e\u003cp\u003eFor UAE readers, it is important to distinguish an online product listing from an approved pharmaceutical medicine. The Abu Dhabi Department of Health issued a 2026 alert stating that retatrutide remained under clinical development and that unauthorized products were not licensed or authorized for use or distribution.\u003c\/p\u003e\u003ch2\u003eQuick Product Overview\u003c\/h2\u003e\u003cp\u003eProduct Information\u003c\/p\u003e\u003cp\u003eDetails\u003c\/p\u003e\u003cp\u003eProduct\u003c\/p\u003e\u003cp\u003eRetatrutide 3D\u003c\/p\u003e\u003cp\u003eCompound\u003c\/p\u003e\u003cp\u003eRetatrutide\u003c\/p\u003e\u003cp\u003eDevelopment code\u003c\/p\u003e\u003cp\u003eLY3437943\u003c\/p\u003e\u003cp\u003eListed strength\u003c\/p\u003e\u003cp\u003e60mg\u003c\/p\u003e\u003cp\u003eListed volume\u003c\/p\u003e\u003cp\u003e3ml\u003c\/p\u003e\u003cp\u003eFormat\u003c\/p\u003e\u003cp\u003ePre-filled pen\u003c\/p\u003e\u003cp\u003ePackaging statement\u003c\/p\u003e\u003cp\u003e1 pen contains 5 doses\u003c\/p\u003e\u003cp\u003eLabel\u003c\/p\u003e\u003cp\u003eFor export only\u003c\/p\u003e\u003cp\u003eProduct category\u003c\/p\u003e\u003cp\u003eInvestigational compound\u003c\/p\u003e\u003cp\u003eUAE context\u003c\/p\u003e\u003cp\u003eRegulatory verification required\u003c\/p\u003e\u003cp\u003eThe product specifications above are taken from the supplied packaging. Current manufacturer, batch, storage and laboratory documentation should be verified separately.\u003c\/p\u003e\u003ch2\u003eWhat Is Retatrutide?\u003c\/h2\u003e\u003cp\u003eRetatrutide is an investigational molecule developed by Eli Lilly. Its scientific feature is activity across three hormone receptor pathways:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eGLP-1\u003c\/li\u003e\n\u003cli\u003eGIP\u003c\/li\u003e\n\u003cli\u003eGlucagon\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eBecause of this combination, retatrutide is generally described as a triple agonist. Lilly states that it is still under investigation and has not been approved by a regulatory agency for public use.\u003c\/p\u003e\u003cp\u003eThe development code LY3437943 is commonly used in clinical-trial records and scientific references.\u003c\/p\u003e\u003ch2\u003eUnderstanding the 60mg\/3ml Pen Format\u003c\/h2\u003e\u003cp\u003eThe supplied packaging identifies this product as 60mg\/3ml and states that one pen contains five doses.\u003c\/p\u003e\u003cp\u003eThat packaging information describes the physical product presentation. It should not be interpreted as a recommendation for how the product should be administered.\u003c\/p\u003e\u003cp\u003eDifferent retatrutide products on the market can vary in strength, volume, pen design and documentation. Current UAE-oriented listings show several retatrutide pen formats, including 30mg, 40mg, 50mg and 60mg presentations.\u003c\/p\u003e\u003cp\u003eFor this reason, the exact product label and batch documentation should always be checked.\u003c\/p\u003e\u003ch2\u003eRetatrutide and Triple-Agonist Biology\u003c\/h2\u003e\u003cp\u003eRetatrutide is being investigated because it combines activity at three receptor systems.\u003c\/p\u003e\u003ch3\u003eGLP-1\u003c\/h3\u003e\u003cp\u003eGLP-1 signaling is associated with appetite regulation, satiety and glucose-related physiological processes.\u003c\/p\u003e\u003ch3\u003eGIP\u003c\/h3\u003e\u003cp\u003eGIP participates in glucose-dependent signaling and metabolic processes.\u003c\/p\u003e\u003ch3\u003eGlucagon\u003c\/h3\u003e\u003cp\u003eGlucagon is involved in energy metabolism and regulation of stored energy.\u003c\/p\u003e\u003cp\u003eResearchers are studying whether simultaneous activity across these pathways can produce meaningful changes in metabolic outcomes. The triple-agonist mechanism is one of the central scientific features distinguishing retatrutide from single- and dual-pathway approaches.\u003c\/p\u003e\u003ch2\u003eRetatrutide Clinical Development\u003c\/h2\u003e\u003cp\u003eRetatrutide has progressed beyond early-stage research into a broad Phase 3 development program.\u003c\/p\u003e\u003cp\u003eClinicalTrials.gov records include studies examining:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eObesity\u003c\/li\u003e\n\u003cli\u003eObesity with type 2 diabetes\u003c\/li\u003e\n\u003cli\u003eSevere obesity with cardiovascular disease\u003c\/li\u003e\n\u003cli\u003eWeight-maintenance outcomes\u003c\/li\u003e\n\u003cli\u003eDose-escalation strategies\u003c\/li\u003e\n\u003cli\u003eComparisons with existing therapies\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eFor example, TRIUMPH-5 is a Phase 3 study comparing retatrutide with tirzepatide in adults with obesity.\u003c\/p\u003e\u003cp\u003eThe existence of these studies demonstrates ongoing clinical development, but it does not mean that every retatrutide product available online is an approved medicine.\u003c\/p\u003e\u003ch2\u003e Retatrutide 3D 60mg UAE and Weight-Management Studies\u003c\/h2\u003e\u003cp\u003eBody-weight change is one of the major outcomes being investigated in retatrutide trials.\u003c\/p\u003e\u003cp\u003eEarlier Phase 2 research showed substantial average weight reductions at 48 weeks compared with placebo, while later Phase 3 studies have reported further results over longer follow-up periods.\u003c\/p\u003e\u003cp\u003eClinical findings should always be interpreted according to:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eStudy population\u003c\/li\u003e\n\u003cli\u003eDose studied\u003c\/li\u003e\n\u003cli\u003eDuration\u003c\/li\u003e\n\u003cli\u003eComparator\u003c\/li\u003e\n\u003cli\u003ePrimary endpoint\u003c\/li\u003e\n\u003cli\u003eSafety findings\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eA trial result represents an average outcome for a defined research population and does not guarantee the same result for an individual.\u003c\/p\u003e\u003ch2\u003eRetatrutide 3D Product Presentation\u003c\/h2\u003e\u003cp\u003eThe supplied product image shows a clean pre-filled pen format with:\u003c\/p\u003e\u003cp\u003eRETATRUTIDE 3D\u003cbr\u003e 60mg\/3ml\u003cbr\u003e 1 pen contains 5 doses\u003c\/p\u003e\u003cp\u003eThe packaging also includes the phrase “For export only.”\u003c\/p\u003e\u003cp\u003eThese details are useful for product identification and cataloging, but packaging language does not establish regulatory approval, authenticity, purity or clinical suitability.\u003c\/p\u003e\u003ch2\u003eProduct Verification and Documentation\u003c\/h2\u003e\u003cp\u003eWhen evaluating a retatrutide product, product-level documentation is particularly important.\u003c\/p\u003e\u003ch3\u003eProduct Identity\u003c\/h3\u003e\u003cp\u003eConfirm the exact compound name and development code where applicable.\u003c\/p\u003e\u003ch3\u003eStrength and Volume\u003c\/h3\u003e\u003cp\u003eVerify that the labeled strength and volume correspond to the actual product.\u003c\/p\u003e\u003ch3\u003eBatch Information\u003c\/h3\u003e\u003cp\u003eLook for a lot or batch number.\u003c\/p\u003e\u003ch3\u003eCertificate of Analysis\u003c\/h3\u003e\u003cp\u003eA batch-specific COA can connect laboratory testing to a specific product lot.\u003c\/p\u003e\u003ch3\u003eLaboratory Testing\u003c\/h3\u003e\u003cp\u003eAvailable analytical documentation may include identity and purity testing. Current UAE peptide suppliers use COA and third-party testing as part of their product documentation.\u003c\/p\u003e\u003ch3\u003eStorage Documentation\u003c\/h3\u003e\u003cp\u003eStorage requirements should come from the exact manufacturer's or supplier's documentation.\u003c\/p\u003e\u003ch2\u003eRetatrutide 3D 60mg UAE and Regulatory Status\u003c\/h2\u003e\u003cp\u003eThe UAE regulatory position is an important part of evaluating this product.\u003c\/p\u003e\u003cp\u003eThe Abu Dhabi Department of Health issued Circular 40\/2026 warning healthcare facilities, healthcare professionals and the public against unauthorized retatrutide products. The circular states that retatrutide remained under clinical development and that unauthorized products were not licensed or authorized for use or distribution.\u003c\/p\u003e\u003cp\u003eThis means:\u003c\/p\u003e\u003cp\u003eOnline listing ≠ regulatory approval\u003c\/p\u003e\u003cp\u003eClinical development ≠ public authorization\u003c\/p\u003e\u003cp\u003eProduct availability ≠ official UAE medicine supply\u003c\/p\u003e\u003cp\u003eFor UAE readers, the current regulatory position should therefore be checked before relying on any retatrutide product listing.\u003c\/p\u003e\u003ch2\u003eHow to Evaluate a Retatrutide Pen Listing\u003c\/h2\u003e\u003cp\u003eA professional product page should make verification straightforward.\u003c\/p\u003e\u003ch3\u003eCheck the Label\u003c\/h3\u003e\u003cp\u003eCompare the product name, strength and volume with the listing.\u003c\/p\u003e\u003ch3\u003eCheck the Batch\u003c\/h3\u003e\u003cp\u003eLook for batch or lot information where available.\u003c\/p\u003e\u003ch3\u003eReview Testing\u003c\/h3\u003e\u003cp\u003eLook for independent or batch-specific laboratory documentation.\u003c\/p\u003e\u003ch3\u003eVerify the Supplier\u003c\/h3\u003e\u003cp\u003eConfirm who manufactured or supplied the product.\u003c\/p\u003e\u003ch3\u003eCheck Regulatory Information\u003c\/h3\u003e\u003cp\u003eUse current UAE authority information rather than relying on social-media or seller claims.\u003c\/p\u003e\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\u003ch3\u003eWhat is Retatrutide 3D 60mg UAE?\u003c\/h3\u003e\u003cp\u003eIt is a product listing identifying a RETATRUTIDE 3D pre-filled pen with 60mg\/3ml shown on the supplied packaging.\u003c\/p\u003e\u003ch3\u003eHow many doses does the package state?\u003c\/h3\u003e\u003cp\u003eThe box states that one pen contains 5 doses.\u003c\/p\u003e\u003ch3\u003eWhat is LY3437943?\u003c\/h3\u003e\u003cp\u003eLY3437943 is the development code associated with retatrutide.\u003c\/p\u003e\u003ch3\u003eWhy is retatrutide called a triple agonist?\u003c\/h3\u003e\u003cp\u003eBecause it is being investigated across GIP, GLP-1 and glucagon receptor pathways.\u003c\/p\u003e\u003ch3\u003eIs retatrutide approved?\u003c\/h3\u003e\u003cp\u003eNo. Lilly currently describes retatrutide as investigational, and the UAE Department of Health has warned against unauthorized retatrutide products.\u003c\/p\u003e\u003ch3\u003eWhat should I verify before evaluating this product?\u003c\/h3\u003e\u003cp\u003eCheck the exact label, strength, volume, batch information, laboratory documentation, COA and current regulatory status.\u003c\/p\u003e\u003ch3\u003eDoes the product packaging prove authenticity?\u003c\/h3\u003e\u003cp\u003eNo. Packaging alone does not establish authenticity, purity, safety or regulatory authorization.\u003c\/p\u003e\u003ch2\u003eConclusion\u003c\/h2\u003e\u003cp\u003eRetatrutide 3D 60mg UAE is a pre-filled pen presentation identified on the supplied packaging as 60mg\/3ml, with the box stating that one pen contains five doses.\u003c\/p\u003e\u003cp\u003eRetatrutide itself is an investigational triple agonist being studied across a growing Phase 3 and Phase 3b clinical program. Research includes obesity, type 2 diabetes, cardiovascular disease and other obesity-related conditions.\u003c\/p\u003e\u003cp\u003eFor UAE readers, the regulatory distinction is essential. The Abu Dhabi Department of Health has specifically warned against unauthorized retatrutide products and states that the compound remains under clinical development.\u003c\/p\u003e\u003cp\u003eA reliable product page should therefore prioritize accurate product identification, transparent documentation, batch traceability and current regulatory information.\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e","brand":"Pharma Testostrone","offers":[{"title":"Default Title","offer_id":44629829156952,"sku":null,"price":1600.0,"currency_code":"AED","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0745\/6315\/8104\/files\/Retatrutide_3D_60mg_UAE_3ml_pre-filled_pen.jpg?v=1788094406","url":"https:\/\/timewell.store\/products\/retatrutide-3d-60mg-uae","provider":"Timewell","version":"1.0","type":"link"}